Skip to main content

Fiscal Wizard · Single-issue tearsheet

ALKS / Jun 21, 2026 Run #7379

ALKS

Alkermes plc

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Composite verdict

B 67.6 / 100
Bullish setup · Trend Following 13 drivers · 2 gates blocking
  • 52-Week Proximity
  • Parabolic SAR Flip
  • Accumulation/Distribution Line
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 8th of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 24 signals0% Bear
Momentum Bullish 98Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -75%
Asset value $10.92Earnings power value $14.64Price $44.99

Priced above its no-growth earnings power value ($14.64/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Weak

35.2 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
FCF Margin 82
Margin of Safety 0
Return on Assets 79
OCF to Net Income 0
Return on Capital Employed 78
Cash Conversion 0

Technicals Bullish

100.0 / 100

Bullish setup leads (52-Week Proximity, Parabolic SAR Flip, Accumulation/Distribution Line); bears gated by guards. · 43 signals shown.

Strongest
Weakest
52-Week Proximity 93
Accumulation/Distribution Line 90
Trendline Break 89

Risk Gates

2 blocking 7 caution

2 guards active, 16 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Piotroski F-Score Caution

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ALKS.